Overview
Laparoscopic sleeve gastrectomy (LSG) is now the most commonly performed bariatric procedure worldwide. Although minimally invasive, patients commonly experience moderate pain in the immediate postoperative period — and notably, studies show the prevalence of moderate-to-severe postoperative pain is higher after LSG than after other comparable laparoscopic procedures, despite standardised anaesthetic and analgesic protocols. This is increasingly performed on an outpatient or overnight-stay basis, making efficient opioid-sparing analgesia clinically important.
PROSPECT 2026 summary (Debel et al., updating the 2019 Macfater guideline; literature search Sept 2018–Feb 2024): Basic multimodal analgesia (paracetamol + NSAID/COX-2) remains foundational. TAP block and gabapentinoids both showed benefit in reducing LSG-specific postoperative pain in the prior review and continue to be supported. Opioid-sparing strategy is a particular priority in this population given the high prevalence of obstructive sleep apnoea (OSA).
OSA & Obesity-Specific Considerations
Obstructive sleep apnoea (OSA) is highly prevalent in the bariatric surgical population — many patients are undiagnosed at the time of surgery. This makes opioid minimisation a clinical priority distinct from most other abdominal procedures: opioid-induced respiratory depression risk is compounded by anatomical airway factors, baseline hypoventilation tendency, and frequently undiagnosed OSA severity.
- Multimodal opioid-sparing analgesia is not optional but essential — TAP block + gabapentinoids + paracetamol + NSAID/COX-2 should all be considered as part of a genuinely opioid-minimising strategy, not simply "nice to have" adjuncts
- Continuous SpO₂ monitoring postoperatively — particularly overnight, given peak OSA-related respiratory events typically occur during sleep
- CPAP continuation postoperatively for patients with known OSA who use it at home
- Elevated head of bed — improves respiratory mechanics in obese patients generally
- Avoid long-acting sedatives/opioids where possible — favour short-acting, titratable agents
Analgesic Pathway
- Paracetamol 1g PO/IV
- NSAID or COX-2 PO (renal function permitting)
- Gabapentin 300mg or Pregabalin 75–150mg PO — supported by evidence for this procedure specifically
- TAP block — bilateral, US or laparoscopic-guided
- Dexamethasone 8 mg IV (PONV prophylaxis + analgesia)
- Paracetamol 1g IV (if not given pre-op)
- IV ketamine — consider for opioid-sparing in selected patients
- Port-site infiltration — adjunct/alternative to TAP
- Paracetamol 1g QDS regular
- NSAID/COX-2 regular ≤5 days if appropriate
- Opioid PRN rescue — minimise, titrate carefully
- Continuous SpO₂ monitoring, especially overnight
- CPAP continuation if used at home
- Early mobilisation, early oral intake (sips) per ERAS-bariatric
✓ Recommended | ◎ Optional/conditional. Based on PROSPECT 2026 (Debel et al. update).
Systemic Analgesia
Paracetamol + NSAID/COX-2 form the basic multimodal foundation, as in most abdominal procedures. The notable addition for LSG specifically is gabapentinoids, which showed analgesic benefit for this procedure in the underlying systematic review — a less common PROSPECT recommendation given concerns about sedation in other populations, but supported here.
| Agent | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Paracetamol | 1 g | IV/PO | QDS | Regular throughout — dose based on actual body weight unless severe obesity (see below) |
| Celecoxib | 200 mg | PO | BD | COX-2 preferred; ≤5 days |
| Gabapentin | 300 mg | PO | Pre-op, then consider postop | Supported specifically for LSG; balance against OSA-related sedation risk — individualise |
| Pregabalin | 75–150 mg | PO | Pre-op | Alternative to gabapentin |
| Dexamethasone | 8 mg | IV | Single intraop | Strong PONV benefit — particularly relevant given high baseline PONV risk in bariatric surgery |
| Oxycodone/Fentanyl | Titrated, minimal | PO/IV PRN | PRN | Rescue only; titrate cautiously given OSA prevalence |
Gabapentinoid caution despite procedure-specific support: While gabapentinoids showed benefit for LSG pain specifically, the sedation/respiratory depression risk discussed in the general Systemic Analgesia: Gabapentinoids section is particularly relevant here given high OSA prevalence. Individualise — consider omitting or using lower doses in patients with confirmed severe OSA, especially if combined with opioids.
TAP Block
TAP block reduced postoperative pain specifically for LSG in the underlying systematic review. Can be performed via standard ultrasound-guided percutaneous technique or laparoscopic-guided (surgeon performs under direct vision intraoperatively) — both approaches show comparable effectiveness in opioid reduction.
See the full TAP block page for complete technique details. For LSG, bilateral subcostal or lateral TAP (depending on port placement) is typical.
Dosing — Adjusted Approach in Obesity
| Agent | Concentration | Volume (per side) | Notes |
|---|---|---|---|
| Ropivacaine | 0.375–0.5% | 15–20 mL | Standard volume; ultrasound depth may be greater in obese patients — adjust needle length/technique accordingly |
| Bupivacaine | 0.25% | 15–20 mL | Alternative; calculate total dose against lean/adjusted body weight |
Laparoscopic-guided vs ultrasound-guided TAP: A comparative study of over 1,200 patients found both UTAP (ultrasound-guided) and LTAP (laparoscopic-guided, surgeon-performed) reduced opioid consumption versus no TAP block, supporting either approach as a valid option depending on operator preference and available expertise.
Drug Dosing Considerations in Obesity
Bariatric surgery patients have altered pharmacokinetics that affect dosing of several common analgesics:
| Drug | Dosing weight basis | Notes |
|---|---|---|
| Paracetamol | Actual body weight (standard 1g dose typically appropriate) | Avoid exceeding 4g/24h regardless of weight; consider dose reduction if hepatic impairment |
| Local anaesthetics (TAP, etc.) | Lean body weight or adjusted body weight | LA distributes poorly into fat — dosing by total body weight risks underestimating relative overdose; many clinicians use lean body weight calculations for max dose safety |
| Opioids | Lean body weight for loading; titrate to effect | Volume of distribution increased for lipophilic opioids (fentanyl); titrate carefully regardless of calculated dose |
| NSAIDs | Standard fixed dose | Not weight-based; standard adult doses apply |
Practical Analgesic Protocol
Suggested protocol for elective laparoscopic sleeve gastrectomy:
References
- Debel N, Snijkers E, Van de Velde M, Joshi GP, Sauter AR, Freys S, Pogatzki-Zahn E; PROSPECT Working Group. Pain management for laparoscopic sleeve gastrectomy: an update of the systematic review and PROSPECT recommendations. Eur J Anaesthesiol. 2026;43(1):19–33. PMID 41078236 ↗
- Macfater H, Xia W, Srinivasa S, et al. Evidence-Based Management of Postoperative Pain in Adults Undergoing Laparoscopic Sleeve Gastrectomy. World J Surg. 2019;43(6):1571–1580. DOI ↗
- Comparing Ultrasound- and Laparoscopic-Guided Transversus Abdominis Plane (TAP) Blocks in Sleeve Gastrectomy Patients. PMC. 2024. PMC11658910 ↗
- A risk factor prediction model for moderate-to-severe postoperative pain in patients undergoing laparoscopic sleeve gastrectomy. PMC. 2025. PMC11813011 ↗
- Grant MC, Gibbons MM, Ko CY, et al. Evidence review for the AHRQ Safety Program for Improving Surgical Care and Recovery: focus on anesthesiology for bariatric surgery. Anesth Analg. 2019.